Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATOMIC: Metformin/Atorvastatin Combination in Type 2 Diabetes and Dyslipidemia
NCT02947620Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Aug 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and dyslipidemia comparing Metformin/Atorvastatin, Metformin and Atorvastatin (3 arms). Primary endpoints: Change in Hemoglobin A1c at 16 weeks and Change in LDL Cholesterol at 16 weeks. Started Aug 2015; status: completed.
02
Drugs
metforminatorvastatin
03
Conditions
type 2 diabetes mellitus (T2DM)dyslipidemia
Beyond the preview
Go deeper on NCT02947620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02947620.